百时美施贵宝、SystImmune报告肺癌试验数据

Bristol Myers Squibb (NYSE:BMY) and SystImmune reported data from an early-stage study testing their bispecific antibody-drug conjugate, iza-bren, as a treatment for advanced non-small cell lung cancer and other solid tumors.

Iza-bren is developed collaboratively by SystImmune and Bristol Myers Squibb, with an exclusive license for regions outside Mainland China.

The trial results indicate that iza-bren shows antitumor effects in patients who have been heavily treated for various tumor types.

The study also reported a manageable safety profile, with any hematologic side effects being addressed through standard medical interventions, and no cases of interstitial lung disease were noted.